(CercleFinance.com) – Sanofi reports positive results from part 2 of the phase IIb STREAM-AD study relating to amlitelimab, which support its potential as the best drug in its class in terms of maintaining response in treatment of atopic dermatitis.
This late-breaking data presented at the 2024 American Academy of Dermatology (AAD) Meeting in San Diego shows sustained improvements in disease signs and symptoms off amlitelimab treatment for 28 weeks.
The French health giant adds that the durability of the response to treatment supports the interest of quarterly dosing and that the sustained reduction in biomarkers suggests that inhibition of OX40L allows lasting control of the disease.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
